Drug Trial Radar · NCT02634307
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,057
Actual
Start
Dec 10, 2015
Primary completion
Jun 1, 2021
Study completion Nov 11, 2021
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Alkermes, Inc.
- First posted
- Dec 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.
Conditions
- Multiple Sclerosis
Interventions
ALKS 8700Drug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
- Number of Participants With Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
- Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
- Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline VisitTime frame: Up to 98 weeks
- Number of Participants With Potentially Clinically Significant Laboratory AbnormalitiesTime frame: From first dose to two weeks after last dose of study drug (Up to 98 weeks)
Locations
115 sites in 10 countries. Site status is shown where the registry gives one.
Alkermes Investigational Site
Cullman, Alabama
Alkermes Investigational Site
Phoenix, Arizona
Alkermes Investigational Site
Phoenix, Arizona
Alkermes Investigational Site
Phoenix, Arizona
Alkermes Investigational Site
Tucson, Arizona
Alkermes Investigational Site
Berkeley, California
Alkermes Investigational Site
Loma Linda, California
Alkermes Investigational Site
Long Beach, California
Alkermes Investigational Site
San Diego, California
Alkermes Investigational Site
Basalt, Colorado
Alkermes Investigational Site
Centennial, Colorado
Alkermes Investigational Site
Denver, Colorado
Alkermes Investigational Site
Middlebury, Connecticut
Alkermes Investigational Site
Stamford, Connecticut
Alkermes Investigational Site
Washington D.C., District of Columbia
Alkermes Investigational Site
Atlantis, Florida
Alkermes Investigational Site
Bradenton, Florida
Alkermes Investigational Site
Jacksonville, Florida
Alkermes Investigational Site
Maitland, Florida
Alkermes Investigational Site
Naples, Florida
Alkermes Investigational Site
Ormond Beach, Florida
Alkermes Investigational Site
Sarasota, Florida
Alkermes Investigational Site
Tampa, Florida
Alkermes Investigational Site
Vero Beach, Florida
Alkermes Investigational Site
Atlanta, Georgia
Alkermes Investigational Site
Atlanta, Georgia
Alkermes Investigational Site
Atlanta, Georgia
Alkermes Investigational Site
Columbus, Georgia
Alkermes Investigational Site
Evanston, Illinois
Alkermes Investigational Site
Indianapolis, Indiana
Alkermes Investigational Site
Indianapolis, Indiana
Alkermes Investigational Site
Des Moines, Iowa
Alkermes Investigational Site
Overland Park, Kansas
Alkermes Investigational Site
Lexington, Kentucky
Alkermes Investigational Site
Alexandria, Louisiana
Alkermes Investigational Site
Baton Rouge, Louisiana
Alkermes Investigational Site
Detroit, Michigan
Alkermes Investigational Site
Traverse City, Michigan
Alkermes Investigational Site
Golden Valley, Minnesota
Alkermes Investigational Site
St Louis, Missouri
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.